mortality/aging
• in LPS-treated mice
|
immune system
• in LPS-treated mice
|
• in LPS-treated mice
|
• LPS-stimulated bone marrow-derived macrophage exhibit decreased CCL5 production comapred with similarly treated wild-type cells
• LPS-treated mice exhibit decreased circulating CCL5 compared with similarly treated wild-type mice
|
• in LPS-stimulated bone marrow-derived macrophage
• in Listeria-exposed macrophages
|
• in LPS-stimulated bone marrow-derived macrophage
• in Listeria-exposed macrophages
|
• in bone marrow-derived macrophage stimulated with LPS or other microbial products
• in Listeria-exposed macrophages
|
• LPS-treated mice exhibit improved survival with increased TNF, IL6, and CCL5 serum levels compared with similarly treated wild-type mice
|
• mice exposed to Listeria monocytogenes exhibit increased liver burden compared with similarly treated wild-type mice
|
homeostasis/metabolism
• in LPS-treated mice
|
• in LPS-treated mice
|
growth/size/body
• slight in young mice
|